Rallybio Deal History & Licensing Activity
Rallybio is a large biotech. Over the past three years, Rallybio has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Other
Focus Area
Immunology
Rallybio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Rallybio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| rare disease / immunology program | Avenzo Therapeutics | Other | Unknown | collaboration | Jun 1, 2026 |
| rare disease program | Avenzo | Other | Unknown | collaboration | Jun 1, 2026 |
| next-generation oncology pipeline | Avenzo Therapeutics | ADC | Unknown | acquisition |
Rallybio Pipeline Focus
Therapeutic areas and modalities where Rallybio is most active based on deal history and clinical trial data.
Therapeutic Areas
Rallybio Strategic Signals
Key indicators of Rallybio's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Rallybio's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
About Rallybio Licensing & Deal Activity
Rallybio is a large biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Rallybio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Rallybio include Immunology (2 deals and trials), Rare Disease (2 deals and trials), and Oncology (2 deals and trials). In terms of modality, Rallybio has shown particular interest in other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Rallybio and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Rallybio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.